
Reset all filters
01 8Gran
02 9Neupogen
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 225
2019 Revenue in Millions : 264
Growth (%) : -15
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 58
2019 Revenue in Millions : 61
Growth (%) : -5
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 168
2020 Revenue in Millions : 225
Growth (%) : -25
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 53
2020 Revenue in Millions : 58
Growth (%) : 3
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 144
2021 Revenue in Millions : 168
Growth (%) : -14
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 62
2021 Revenue in Millions : 53
Growth (%) : 17
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 47
2022 Revenue in Millions : 62
Growth (%) : -16
Main Therapeutic Indication : Hematology
Currency : USD
2024 Revenue in Millions : 35
2023 Revenue in Millions : 47
Growth (%) : -24
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 1,159
2014 Revenue in Millions : 1,049
Growth (%) : -9%
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 549
2016 Revenue in Millions : 765
Growth (%) : -28